Rosacea is a common, chronic dermatologic condition that most commonly affects sun-sensitive, pale-skinned individuals of Northern or Eastern European
descent and those of Celtic heritage.1-3There is no clearly identified cause or cure for rosacea; therefore, this condition is managed rather than cured.4-6Triggers such as weather, ultraviolet
radiation, medications, emotional stress, spicy foods, alcohol
consumption, menopause, and strong emotions are known to
induce the skin changes. Commonly, patients present with central facial vasodilation causing flushing and ultimately persistent telangiectasias, whereas others have acne, including papules and pustules. These findings are the 2 main components
associated with the diagnosis of rosacea. The papular/pustular,
or inflammatory, component responds to topical antibiotics,
and light-based treatments are often effective for the telangiectasias. There is currently no topical treatment that has the ability
to completely clear the redness associated with rosacea.
Current rosacea treatment options include topical antibiotics
(metronidazole and sulfur-containing compounds), topical azelaic acid, oral antibiotics (tetracycline class), and light-based
treatments, specifically intense pulsed light and pulsed dye laser.
Some therapies seem counterintuitive yet have had successful
anecdotal reports, such as the use of a retinoid. Clinically, we
understand that most rosacea patients have naturally sensitive skin that could worsen with the application of an irritating
retinoid. However, it has been suggested that photodamage may play a role in rosacea. Retinoids have been shown histologically to improve and repair photodamage; theoretically,
they may be helpful.7
Clindamycin phosphate 1.2% and tretinoin 0.025% gel (ZIANA;
Medicis Pharmaceutical Corporation, Scottsdale, AZ) is approved by the US Food and Drug Administration for acne
vulgaris and may have a role in rosacea therapy. Due to its
retinoid component, the investigators hope to demonstrate this
treatment's efficacy and lack of irritancy in rosacea patients. This
trial looks at tolerability and therapeutic efficacy of clindamycin
phosphate 1.2% and tretinoin 0.025% gel in rosacea subjects.
Thirty subjects with a clinical presentation of rosacea were recruited. Subjects included were between the ages of 18 and 65
years, in good health other than inflammatory rosacea, had
Fitzpatrick skin types I to III, a tendency to flush or blush easily,
and had persistent redness in the central portion of the face.
Subjects had to be willing and able to avoid excessive sun exposure and commit to all follow-up visits for the duration of the
study. Subjects also had to be willing to allow the study sponsor to use and distribute the photos/images for education and
information purposes, general and or professional advertising,
publicity and promotional purposes, including distribution to
the media and in publication of the scientific work. After explaining the nature of the study, subjects read, signed, and
received a copy of the informed consent.
↑ back to top